Table 6.

The typical and clinically developed MMPs inhibitors in cancer therapy

Drug	Highest phase	Indications	Identifier	Status
COL-3 (NSC-683551)	I	Lymphoma, melanoma, neoplasm metastasis, renal cell carcinoma	NCT00001683	Completed
	I	Unspecified adult solid tumor, protocol specific	NCT00003721	Completed
Neovastat (AE-941)	III	Kidney cancer	NCT00005995	Completed
	III	Adenocarcinoma of the lung, adenosquamous cell lung cancer, large-cell lung cancer, squamous cell lung cancer, stage IIIA non-small cell lung cancer, stage IIIB non-small cell lung cancer	NCT00005838	Completed
Prinomastat (AG3340)	III	Lung cancer	NCT00004199	Completed
	III	Prostate cancer	NCT00003343	Completed
	II	Brain and central nervous system tumors	NCT00004200	Completed
Marimastat (BB-2516)	III	Lung cancer	NCT00003011	Completed
	III	Lung cancer	NCT00002911	Completed
	III	Breast cancer	NCT00003010	Completed
BMS-275291	II/III	Lung cancer	NCT00006229	Completed
Metastat(COL-3)	I/II	Brain and central nervous system tumors	NCT00004147	Completed

Source: All the information is derived from ClinicalTrials.gov (https://www.clinicaltrials.gov)